Yellow fever

References

Key articles

Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Abstract

Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Abstract

World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper - June 2013. Wkly Epidemiol Rec. 2013;88:269-284.Full text  Abstract

Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.Full text  Abstract

Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434-444. Abstract

Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].Full text

Reference articles

1. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.Full text  Abstract

2. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Abstract

3. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Abstract

4. World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper - June 2013. Wkly Epidemiol Rec. 2013;88:269-284.Full text  Abstract

5. World Health Organization. Disease outbreak news. Yellow fever - Mali. December 2019 [internet publication].Full text

6. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2017 [internet publication].Full text

7. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2019 [internet publication].Full text

8. World Health Organization. Winning the war against yellow fever. November 2016 [internet publication].Full text

9. World Health Organization. Weekly epidemiological record. Yellow fever in Africa and the Americas, 2017. August 2018 [internet publication].Full text

10. Wilder-Smith A, Monath TP. Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017;17:248-250.Full text  Abstract

11. Centers for Disease Control and Prevention (CDC). Health information for international travel (Yellow Book). Chapter 4: travel-related infectious diseases, Yellow fever. August 2019 [internet publication].Full text

12. World Health Organization. Yellow fever in the WHO African and American Regions, 2010. Wkly Epidemiol Rec. 2011;86:370-376.Full text  Abstract

13. World Health Organization: Global Response and Alert (GAR). Yellow fever: a current threat. 2017 [internet publication].Full text

14. Vasconcelos PF, Costa ZG, Travassos da Rosa ES, et al. Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. J Med Virol. 2001;65:598-604. Abstract

15. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411. Abstract

16. Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization - recommendations of the ACIP. MMWR Recomm Rep. 2011;60:1-64.Full text  Abstract

17. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.Full text  Abstract

18. Centers of Disease Control and Prevention. Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:324-325.Full text  Abstract

19. Cornet JP, Huard M, Camicas JL, et al. Experimental transmission of the yellow fever virus by the tick Amblyomma variegatum (F.). Bull Soc Pathol Exot Filiales. 1982;75:136-140. Abstract

20. Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.Full text  Abstract

21. World Health Organization. Updates on yellow fever vaccination recommendations for international travelers related to the current situation in Brazil. May 2018 [internet publication].Full text

22. Centers for Disease Control and Prevention. Clinical update: temporary total depletion of US licensed yellow fever vaccine addressed by availability of Stamaril vaccine at selected clinics. April 2019 [internet publication].Full text

23. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434-444. Abstract

24. Grobusch MP, Goorhuis A, Wieten RW, et al. Yellow fever revaccination guidelines change - a decision too feverish? Clin Microbiol Infect. 2013;19:885-886. Abstract

25. World Health Organization Department of Immunization, Vaccines and Biologicals. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. July 2016 [internet publication].Full text

26. Casey RM, Harris JB, Ahuka-Mundeke S, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report. N Engl J Med. 2019 Aug 1;381(5):444-454.Full text  Abstract

27. Roukens AHE, van Halem K, de Visser AW, et al. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018 Nov 27 [Epub ahead of print]. Abstract

28. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine. 2011;29:4544-4555. Abstract

29. Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68:1267-1271. Abstract

30. Traiber C, Coelho-Amaral P, Ritter VR, et al. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J). 2011;87:269-272. Abstract

31. Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;(1):CD010929.Full text  Abstract

32. Nascimento Silva JR, Camacho LA, Siqueira MM, et al; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29:6327-6334. Abstract

33. Medicines and Healthcare products Regulatory Agency. Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older. April 2019 [internet publication].Full text

34. Mirzaian E, Durham MJ, Hess K, et al. Mosquito-borne illnesses in travelers: a review of risk and prevention. Pharmacotherapy. 2010;30:1031-1043. Abstract

35. Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization - recommendations of the ACIP. MMWR Recomm Rep. 2011;60:1-64.Full text  Abstract

36. Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].Full text

37. Drosten C, Göttig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-2330.Full text  Abstract

38. Domingo C, Patel P, Yillah J, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50:4054-4060. Abstract

39. World Health Organization. CDC and WHO launch trial version of a new ELISA: a kit, simpler and faster to perform. July 2018 [internet publication].Full text

40. Drosten C, Göttig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-2330.Full text  Abstract

41. Domingo C, Patel P, Yillah J, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50:4054-4060. Abstract

42. World Health Organization.Yellow fever: case definitions for public health surveillance. May 2015 [internet publication].Full text

43. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS): yellow fever - 1997 case definition. 1997 [internet publication].Full text

44. Centers for Disease Control and Prevention. Yellow fever: diagnostic testing. August 2015 [internet publication].Full text

45. Monath TP. Treatment of yellow fever. Antiviral Res. 2008;78:116-124. Abstract

46. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11(suppl 4):S750-S761. Abstract

47. Arroyo JI, Apperson SA, Cropp CB, et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg. 1988;38:647-650. Abstract

48. Julander JG. Experimental therapies for yellow fever. Antiviral Res. 2013;97:169-179. Abstract

49. Centers for Disease Control and Prevention. Testing of selected patients with serious adverse events potentially related to yellow fever vaccination. August 2015 [internet publication].Full text

50. Borio L, Inglesby T, Peters CJ, et al; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391-2405. Abstract

51. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination: United States, 2001-2002. MMWR Morb Mortal Wkly Rep. 2002;51:989-993.Full text  Abstract

52. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659-666. Abstract

53. ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190:1821-1827.Full text  Abstract

54. Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet. 2001;358:84-85. Abstract

55. Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill. 2004;9:E11-E12.Full text  Abstract

Use of this content is subject to our disclaimer